← Back to News

Strategic partnership between AaviGen and the German Primate Center (DPZ) enabled development of heart-specific adeno- associated viral (AAV) capsids in human-relevant models


Heidelberg, Germany January 24, 2023 – AaviGen, a preclinical stage biotechnology company focused on the development of curative gene therapies for cardiovascular and cardiopulmonary diseases, announced that the strategic partnership with the German Primate Center (DPZ) successfully enabled the development of heart-specific adeno-associated viral (AAV) capsids in non-human primates via AaviGen’s next-generation Cardiac AAV Platform (next-CAP).

“We are excited to work side-by-side with our internationally renowned partner and expert in cardiovascular gene therapy development Prof. Dr. Rabea Hinkel and her experienced team at the DPZ to develop therapeutic solutions for yet incurable rare and common cardiac diseases” explains Prof. Dr. Patrick Most, AaviGen’s CEO. “Working with AaviGen at the forefront of heart-directed gene therapy concepts in human-relevant model systems advances our translational capabilities with access to a novel class of engineered therapeutic vector systems that are key for future effective, safe and easy to administer precision gene therapies against cardiac disorders” replied Prof. Dr. Rabea Hinkel, Director of the DPZ Laboratory Animal Science Unit.

AaviGen and the DPZ will continue their innovative collaborative work on next-generation cardiac gene therapy medicinal product development in human-relevant model systems and accelerate the path to clinical solutions by the creation of synergies.

About AaviGen

AaviGen was founded in 2019 on the understanding that successful gene therapy requires optimized delivery of therapeutic targets to the diseased heart. AaviGen’s scientific approach is documented in numerous peer-reviewed scientific publications and validated by its founders’ track record in scientific innovations for the diagnosis and treatment of cardiac diseases, including gene therapy medicinal products. For more information, please see: www.aavigen.com

About DPZ

The German Primate Center GmbH (DPZ) – Leibniz Institute for Primate Research conducts biological and biomedical research on and with primates in the fields of infection research, neuroscience and primate biology. The DPZ also maintains four field stations in the tropics and is a reference and service center for all aspects of primate research. The DPZ is one of the 97 research and infrastructure facilities of the Leibniz Association.

AaviGen Investor and Media Contact

Prof. Dr. Marc Lerchenmüller, Chief Financial Officer and Managing Director AaviGen, Heidelberg, Germany
T: +49 6221 568900
M: +49 151 51646589


AaviGen’s Forward-Looking Statements

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.